Talphera (ACRX) Revenue & Revenue Breakdown
Talphera Revenue Highlights
Latest Revenue (Y)
$651.00K
Latest Revenue (Q)
$117.00K
Main Segment (Y)
Product
Talphera Revenue by Period
Talphera Revenue by Year
Date | Revenue | Change |
---|---|---|
2023-12-31 | $651.00K | -63.24% |
2022-12-31 | $1.77M | -37.15% |
2021-12-31 | $2.82M | -47.97% |
2020-12-31 | $5.42M | 136.61% |
2019-12-31 | $2.29M | 6.42% |
2018-12-31 | $2.15M | -73.10% |
2017-12-31 | $8.00M | -53.94% |
2016-12-31 | $17.36M | -9.89% |
2015-12-31 | $19.26M | 269.24% |
2014-12-31 | $5.22M | -82.32% |
2013-12-31 | $29.50M | 1132.33% |
2012-12-31 | $2.39M | 123.32% |
2011-12-31 | $1.07M | 100.00% |
2010-12-31 | - | 100.00% |
2009-12-31 | - | 100.00% |
2008-12-31 | - | - |
Talphera Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2023-09-30 | $117.00K | -53.75% |
2023-06-30 | $253.00K | 100.00% |
2023-03-31 | - | -100.00% |
2022-12-31 | $252.00K | -50.30% |
2022-09-30 | $507.00K | -11.05% |
2022-06-30 | $570.00K | 28.96% |
2022-03-31 | $442.00K | 22000.00% |
2021-12-31 | $2.00K | -99.89% |
2021-09-30 | $1.86M | 320.32% |
2021-06-30 | $443.00K | -13.31% |
2021-03-31 | $511.00K | -30.76% |
2020-12-31 | $738.00K | -46.05% |
2020-09-30 | $1.37M | -53.21% |
2020-06-30 | $2.92M | 657.51% |
2020-03-31 | $386.00K | -18.74% |
2019-12-31 | $475.00K | -21.88% |
2019-09-30 | $608.00K | -35.39% |
2019-06-30 | $941.00K | 255.09% |
2019-03-31 | $265.00K | -56.77% |
2018-12-31 | $613.00K | 62.60% |
2018-09-30 | $377.00K | -53.91% |
2018-06-30 | $818.00K | 138.48% |
2018-03-31 | $343.00K | -53.65% |
2017-12-31 | $740.00K | -50.24% |
2017-09-30 | $1.49M | -44.08% |
2017-06-30 | $2.66M | -14.47% |
2017-03-31 | $3.11M | -51.69% |
2016-12-31 | $6.43M | 91.18% |
2016-09-30 | $3.37M | -25.71% |
2016-06-30 | $4.53M | 49.79% |
2016-03-31 | $3.02M | 74.86% |
2015-12-31 | $1.73M | -88.79% |
2015-09-30 | $15.43M | 701.87% |
2015-06-30 | $1.92M | 962.98% |
2015-03-31 | $181.00K | -19.91% |
2014-12-31 | $226.00K | -95.32% |
2014-09-30 | $4.83M | 6695.77% |
2014-06-30 | $71.00K | -25.26% |
2014-03-31 | $95.00K | -99.66% |
2013-12-31 | $27.61M | 4937.77% |
2013-09-30 | $548.00K | 34.64% |
2013-06-30 | $407.00K | -56.70% |
2013-03-31 | $940.00K | -43.88% |
2012-12-31 | $1.68M | 909.04% |
2012-09-30 | $166.00K | -25.89% |
2012-06-30 | $224.00K | -31.91% |
2012-03-31 | $329.00K | -47.28% |
2011-12-31 | $624.00K | 52.94% |
2011-09-30 | $408.00K | 920.00% |
2011-06-30 | $40.00K | 100.00% |
2011-03-31 | - | 100.00% |
2010-12-31 | - | 100.00% |
2010-09-30 | - | 100.00% |
2010-06-30 | - | 100.00% |
2010-03-31 | - | 100.00% |
2009-12-31 | - | - |
Talphera Revenue Breakdown
Talphera Revenue Breakdown by Product
Annual Revenue by Product
Product/Service | Dec 22 | Dec 21 | Dec 20 | Dec 19 | Dec 18 |
---|---|---|---|---|---|
Contract and Other Collaboration | - | $1.81M | $459.00K | - | - |
ZALVISO | - | $270.00K | $1.11M | $1.45M | - |
Royalty | - | $28.00K | $104.00K | - | - |
Product | $1.77M | $1.00M | $1.83M | - | - |
DZUVEO | $183.00K | - | - | - | - |
Non-cash Royalty | - | $83.00K | $312.00K | - | - |
License | - | $1.70M | - | - | - |
DSUVIA | $1.59M | $735.00K | $377.00K | - | - |
Contract and Other Revenue | - | $6.00K | $43.00K | - | - |
Amended License Agreement | - | - | $3.68M | - | - |
Royalty Revenue | - | - | - | - | $385.00K |
Contract and Other | - | - | - | - | $838.00K |
Collaboration Agreement Revenue | - | - | - | - | $1.31M |
Quarterly Revenue by Product
Product/Service | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | Jun 18 | Mar 18 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Product | $252.00K | $507.00K | $570.00K | $442.00K | $2.00K | $160.00K | $392.00K | $451.00K | $116.00K | $55.00K | $47.00K | - | - | - | - | - | - | - | - | - |
DSUVIA | $224.00K | $478.00K | $444.00K | $442.00K | $2.00K | $160.00K | $392.00K | $181.00K | - | - | - | - | - | - | - | - | - | - | - | - |
DZUVEO | $28.00K | $29.00K | $126.00K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Contract and Other Collaboration | - | - | - | - | - | $1.70M | $51.00K | $60.00K | - | - | - | - | - | - | - | - | - | - | - | - |
ZALVISO | - | - | - | - | - | - | - | $270.00K | $340.00K | $352.00K | $301.00K | - | - | - | - | - | - | - | - | - |
Non-cash Royalty | - | - | - | - | - | - | $38.00K | $45.00K | - | - | - | - | - | - | - | - | - | - | - | - |
Royalty | - | - | - | - | - | - | $13.00K | $15.00K | - | - | - | - | - | - | - | - | - | - | - | - |
License | - | - | - | - | - | $1.70M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Contract and Other Revenue | - | - | - | - | - | $6.00K | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Amended License Agreement | - | - | - | - | - | - | - | - | $339.00K | $352.00K | $2.87M | $119.00K | $217.00K | $444.00K | $728.00K | $107.00K | - | - | - | - |
Royalty Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $48.00K | $158.00K | $111.00K | $92.00K | - | - | - |
Collaboration Agreement Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $511.00K | $177.00K | $351.00K | $274.00K |
Contract and Other | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $102.00K | $200.00K | $467.00K | $69.00K |
Talphera Revenue Breakdown by Country
Quarterly Revenue by Country
Country | Dec 22 |
---|---|
DZUVEO | $28.00K |
Product | $252.00K |
DSUVIA | $224.00K |
Talphera Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
CTLT | Catalent | $4.38B | $1.07B |
AMRX | Amneal Pharmaceuticals | $2.39B | $701.78M |
TLRY | Tilray Brands | $788.94M | $188.34M |
ORGO | Organogenesis | $433.14M | $130.23M |
ASRT | Assertio | $152.07M | $31.13M |
LFCR | Lifecore Biomedical | $128.26M | $35.70M |
ALIM | Alimera Sciences | $80.75M | $23.01M |
AQST | Aquestive Therapeutics | $50.58M | $20.10M |
AGRX | Agile Therapeutics | $19.59M | $5.58M |
GHSI | Guardion Health Sciences | $12.25M | $36.35K |
EVOK | Evoke Pharma | $5.18M | $1.74M |
ADMP | Adamis Pharmaceuticals | $4.76M | $9.06M |
ACRX | Talphera | $651.00K | $117.00K |
LSDI | Lucy Scientific Discovery | $7.05K | $9.68K |
SHPH | Shuttle Pharmaceuticals | - | - |
ACRX Revenue FAQ
What is Talphera’s yearly revenue?
Talphera's yearly revenue for 2023 was $651K, representing a decrease of -63.24% compared to 2022. The company's yearly revenue for 2022 was $1.77M, representing a decrease of -37.15% compared to 2021. ACRX's yearly revenue for 2021 was $2.82M, representing a decrease of -47.97% compared to 2020.
What is Talphera’s quarterly revenue?
Talphera's quarterly revenue for Q3 2023 was $117K, a -53.75% decrease from the previous quarter (Q2 2023), and a -76.92% decrease year-over-year (Q3 2022). The company's quarterly revenue for Q2 2023 was $253K, a 100.00% increase from the previous quarter (Q1 2023), and a -55.61% decrease year-over-year (Q2 2022). ACRX's quarterly revenue for Q1 2023 was $0, a -100.00% decrease from the previous quarter (Q4 2022), and a -100.00% decrease year-over-year (Q1 2022).
What is Talphera’s revenue growth rate?
Talphera's revenue growth rate for the last 3 years (2021-2023) was -76.90%, and for the last 5 years (2019-2023) was -71.56%.
What are Talphera’s revenue streams?
Talphera's revenue streams in c 22 are Product, DZUVEO, and DSUVIA. Product generated $1.77M in revenue, accounting 50.00% of the company's total revenue, up 76.22% year-over-year. DZUVEO generated $183K in revenue, accounting 5.17% of the company's total revenue DSUVIA generated $1.59M in revenue, accounting 44.83% of the company's total revenue, up 116.05% year-over-year.
What is Talphera’s main source of revenue?
For the fiscal year ending Dec 22, the largest source of revenue of Talphera was Product. This segment made a revenue of $1.77M, representing 50.00% of the company's total revenue.